This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

US Oncology Going Private

US Oncology (USON) agreed to be taken private at $15.05 a share cash by buyout giant Welsh Carson Anderson & Stowe.

The price is an 18% premium to the Friday close of $12.70 and should spark the shares' second double-digit percentage gain in five months after they went from $7.80 to $10.99 on Oct. 31, 2003, following positive quarterly earnings. The 52-week range is $6.60 to $14.

Two analysts surveyed by Thomson One Analytics produced a mean earnings estimate for US Oncology of 92 cents a share for 2004, implying a profit multiple of 16.3 in Welsh Carson's price. It's slightly less than the $2 billion in revenue the company did last year.

The total value of Monday's buyout is $1.7 billion including stock options and assumed debt. Welsh Carson already owns about 14.5% of US Oncology's common stock. Several members of the company's current management team, including CEO Dale Ross, will continue as employees of the private company and "be given the opportunity to purchase equity securities and have the benefits of being granted restricted stock and stock options in such entity and participation in other incentive plans."

The buyout is the latest in a series of going-private transactions that have occurred despite a yearlong bull market. Extended Stay America (ESA) has agreed to be bought by Blackstone Group in a deal worth about $19.63 a share while drugstore chain Duane Reade (DRD) is being bought by a fund started by the Texas Bass family for $17 a share. AMF Bowling (ABWI) is being taken out at $25 a share by Chicago's Code Hennessy.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $92.17 -1.10%
FB $118.91 0.93%
GOOG $707.94 0.93%
TSLA $215.05 1.70%
YHOO $37.08 0.38%


Chart of I:DJI
DOW 17,685.61 +24.90 0.14%
S&P 500 2,050.59 -0.04 -0.00%
NASDAQ 4,711.58 -5.5140 -0.12%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs